SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
RZLT reported Fourth Quarter and Full Year Fiscal 2026 (ended June 30, 2026) results. The price and volatility reaction is pending.
RZLTearnings

Earnings reactions, page 16

Rezolute, Inc. (RZLT) Q4 FY2026 earnings

September 25, 2026 · SharpeIQ Research Desk

Reported results

  • Full fiscal year 2026 R&D expenses were $53.8 million compared to $61.5 million in fiscal year 2025; Q4 FY2026 R&D expenses were $14.9 million compared with $20.9 million in Q4 FY2025.
  • Full fiscal year 2026 G&A expenses were $29.2 million compared to $18.4 million in fiscal year 2025; Q4 FY2026 G&A expenses were $6.7 million compared with $5.0 million in Q4 FY2025.
  • Full year fiscal 2026 net loss was $77.6 million compared to net loss of $74.4 million for fiscal year 2025; Q4 FY2026 net loss was $20.5 million compared with $24.4 million in Q4 FY2025.
  • Cash, cash equivalents and investments in marketable securities were $107.8 million as of June 30, 2026, compared with $167.9 million as of June 30, 2025.
  • Full fiscal year 2026 basic and diluted net loss per common share was $(0.75) compared to $(0.98) in fiscal year 2025; Q4 FY2026 was $(0.20) compared with $(0.26) in Q4 FY2025.
  • As of June 30, 2026, accumulated deficit was $(481.4) million and total stockholders’ equity was $100.7 million.

Guidance

  • Topline results from the upLIFT Phase 3 study in tumor HI expected before the end of 2026.

Notes

As of June 2026, 7 of 8 enrolled participants in upLIFT met responder criterion for primary endpoint; 1 participant withdrew consent prior to completion of pivotal treatment phase. Data from Phase 3 sunRIZE study in congenital HI did not meet its primary endpoint and remains under FDA review.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-09-24 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →